Although further studies are warranted to validate these findings, our results suggest that determination of the GPS and BMI may aid in predicting treatment outcome for patients with NSCLC and high PD‐L1 expression who are administered first‐line treatment with pembrolizumab monotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.